124 related articles for article (PubMed ID: 38191019)
21. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary.
Wolf JK; Mullen J; Eifel PJ; Burke TW; Levenback C; Gershenson DM
Gynecol Oncol; 1999 Apr; 73(1):35-41. PubMed ID: 10094877
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and oncological outcomes of recurrent adult granulosa cell tumor of ovary: A retrospective study of seventy patients.
Gu Y; Wang D; Jia C; Chen L; Cang W; Wan X; Yang J; Xiang Y
Acta Obstet Gynecol Scand; 2023 Jun; 102(6):782-790. PubMed ID: 37012211
[TBL] [Abstract][Full Text] [Related]
23. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2021 Aug; 162(2):345-352. PubMed ID: 34045053
[TBL] [Abstract][Full Text] [Related]
24. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
25. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
[TBL] [Abstract][Full Text] [Related]
28. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
[TBL] [Abstract][Full Text] [Related]
29. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
30. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of recurrent/relapsed ovarian granulosa cell tumor: a single-center experience.
Al-Badawi IA; Abu-Zaid A; Azzam A; AlOmar O; AlHusaini H; Amin T
J Obstet Gynaecol Res; 2014 Sep; 40(9):2066-75. PubMed ID: 25181627
[TBL] [Abstract][Full Text] [Related]
31. Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors.
Wang D; Cao D; Jia C; Huang H; Yang J; Wu M; Pan L; Shen K; Xiang Y
Gynecol Oncol; 2018 Nov; 151(2):275-281. PubMed ID: 30219238
[TBL] [Abstract][Full Text] [Related]
32. Maximum surgical effort is warranted for recurrent adult granulosa cell tumors of ovary.
Karalok A; Ureyen I; Tasci T; Basaran D; Turkmen O; Boran N; Cirik DA; Kimyon G; Tulunay G; Turan T
Tumori; 2016 Aug; 102(4):404-8. PubMed ID: 27174627
[TBL] [Abstract][Full Text] [Related]
33. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
Harter P; Sehouli J; Vergote I; Ferron G; Reuss A; Meier W; Greggi S; Mosgaard BJ; Selle F; Guyon F; Pomel C; Lécuru F; Zang R; Avall-Lundqvist E; Kim JW; Ponce J; Raspagliesi F; Kristensen G; Classe JM; Hillemanns P; Jensen P; Hasenburg A; Ghaem-Maghami S; Mirza MR; Lund B; Reinthaller A; Santaballa A; Olaitan A; Hilpert F; du Bois A;
N Engl J Med; 2021 Dec; 385(23):2123-2131. PubMed ID: 34874631
[TBL] [Abstract][Full Text] [Related]
34. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Cancer; 1995 Nov; 76(9):1606-14. PubMed ID: 8635065
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
Gockley A; Melamed A; Cronin A; Bookman MA; Burger RA; Cristae MC; Griggs JJ; Mantia-Smaldone G; Matulonis UA; Meyer LA; Niland J; O'Malley DM; Wright AA
Am J Obstet Gynecol; 2019 Dec; 221(6):625.e1-625.e14. PubMed ID: 31207237
[TBL] [Abstract][Full Text] [Related]
36. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
37. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS
N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393
[TBL] [Abstract][Full Text] [Related]
38. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary.
Mangili G; Ottolina J; Gadducci A; Giorda G; Breda E; Savarese A; Candiani M; Frigerio L; Scarfone G; Pignata S; Rossi R; Marinaccio M; Lorusso D
Br J Cancer; 2013 Jul; 109(1):29-34. PubMed ID: 23756859
[TBL] [Abstract][Full Text] [Related]
40. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]